Species Difference in the Metabolism of Mulberrin in Vitro and Its Inhibitory Effect on Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes

被引:1
作者
Hu, Jiayin [1 ]
Hu, Tingting [1 ]
Guo, Zhe [1 ]
Song, Yonggui [2 ]
Shan, Lina [1 ]
Shi, Xianbao [1 ]
机构
[1] Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou 121001, Peoples R China
[2] Jiangxi Univ Tradit Chinese Med, 1688 Meiling Rd, Nanchang 330006, Peoples R China
关键词
CYP; uridine 5'-diphosphate (UDP)-glucuronosyltransferase; liver microsome; interspecies dif-ference; mulberrin; Western blot analysis; DRUG-DRUG INTERACTIONS; HUMAN LIVER-MICROSOMES; HEPATIC-CLEARANCE; CANCER; GLUCURONIDATION; CYP3A4; UGT; IDENTIFICATION; CONSTITUENTS; PREVALENCE;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study aimed to evaluate the interspecies difference in metabolism of mulberrin and examine the interaction between mulberrin and CYP enzymes or recombinant human uridine 5'-diphosphate (UDP)minipig (PLMs), monkey (MLMs), rabbit (RLMs), rat (RAMs), and mouse (MIMs) were used to investigate metabolic diversity among different species. Additionally, recombinant human supersomes were used to confirm that metabolic enzymes are involved in the biotransformation of mulberrin. We also evaluated the influence of mulberrin on protein expression by Western blot analysis. Mulberrin metabolism showed significant interspecies differences. We found four and two metabolites in phase I and II reaction systems, respectively. In phase I metabolism profiles of mulberrin for HLMs, PLMs and MLMs conformed to the classic Michaelis-Menten kinetics, RAMs and MIMs followed biphasic kinetics; phase II reaction of mulberrin in HLMs, DLMs, PLMs, MLMs, RLMs, RAMs and MIMs followed biphasic kinetics. UGT1A1 were the major CYP isoforms responsible for the metabolism of mulberrin. Mulberrin showed potent inhibitory effects against CYP3A4, CYP2C9, CYP2E1, UGT1A1, UGT1A3 and UGT2B7 with IC50 values of 54.21, 9.93, 39.12, 3.84, 2.01, 16.36 mu M, respectively. According to Western blot analysis, mulberrin can upregulate the protein expression of CYP2C19, and downregulate the expression levels of CYP3A5 and CYP2C9 in HepG2 cells as concentration increased. The interspecies comparisons can help find other species with metabolic pathways similar to those in humans for future in vivo studies.
引用
收藏
页码:669 / 678
页数:10
相关论文
共 56 条
  • [51] Regioselective glucuronidation of gingerols by human liver microsomes and expressed UDP-glucuronosyltransferase enzymes: reaction kinetics and activity correlation analyses for UGT1A9 and UGT2B7
    Wu, Zhufeng
    Liu, Hongming
    Wu, Baojian
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2015, 67 (04) : 583 - 596
  • [52] Mulberrin (Mul) reduces spinal cord injury (SCI)-induced apoptosis, inflammation and oxidative stress in rats via miroRNA-337 by targeting Nrf-2
    Xia, Peng
    Gao, Xu
    Duan, Lian
    Zhang, Wei
    Sun, Yi-Fu
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 : 1480 - 1487
  • [53] Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism
    Zhang, Feng
    Huang, Jian
    He, Rong-Jing
    Wang, Lu
    Huo, Peng-Chao
    Guan, Xiao-Qing
    Fang, Sheng-Quan
    Xiang, Yan-Wei
    Jia, Shou-Ning
    Ge, Guang-Bo
    [J]. PHYTOMEDICINE, 2020, 77
  • [54] C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes
    Zhang, Y. -Y.
    Liu, Y.
    Zhang, J. -W.
    Ge, G. -B.
    Liu, H. -X.
    Wang, L. -M.
    Sun, J.
    Yang, L.
    [J]. XENOBIOTICA, 2009, 39 (12) : 903 - 914
  • [55] Inhibition of in vitro metabolism of testosterone in human, dog and horse liver microsomes to investigate species differences
    Zielinski, Jana
    Mevissen, Meike
    [J]. TOXICOLOGY IN VITRO, 2015, 29 (03) : 468 - 478
  • [56] Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
    Zurth, Christian
    Koskinen, Mikko
    Fricke, Robert
    Prien, Olaf
    Korjamo, Timo
    Graudenz, Kristina
    Denner, Karsten
    Bairlein, Michaela
    Von Buehler, Clemens-Jeremias
    Wilkinson, Gary
    Gieschen, Hille
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (06) : 747 - 759